SPOTLIGHT -
Executive Director of Clinical Science, Regor Pharmaceuticals, Inc.
FDA’s New Diversity Plan Guidance, And What It Means for Sponsors Developing Cancer Drugs
Guidance will compel sponsors to consider new enrollment strategies and to be more diverse.
